Clinical Characteristics and Outcome of Methamphetamine-Associated Pulmonary Arterial Hypertension and Dilated Cardiomyopathy

JACC. Heart Failure
Susan X ZhaoMichael H Crawford

Abstract

This study sought to characterize patients with methamphetamine-associated pulmonary arterial hypertension (MA-PAH) and cardiomyopathy (MA-CMP), to compare with MA controls (MA-CTL), users with structurally normal hearts, with the aim of identifying risk factors for these conditions. MA-PAH and MA-CMP are 2 poorly understood cardiac complications in MA users. We retrospectively studied the clinical characteristics and outcomes of 50 MA-PAH, 296 MA-CMP, and 356 MA-CTL patients, whom we evaluated between 2010 and 2017. After a median follow-up of 20.0 months (interquartile range [IQR]: 7.6 to 42.6 months), all-cause mortality was 18.0% for MA-PAH, 15.2% for MA-CMP, and 4.5% for MA-CTL group (p < 0.001). More women (58%) were in the MA-PAH group than in the MA-CMP (14%; p < 0.001) and MA-CTL (42%; p = 0.028) groups, whereas the MA-CMP group was predominantly male (86% vs. 58% in the MA-CTL group; p < 0.001). More MA-CMP patients had hypertension (p < 0.001) or alcoholism (p < 0.001) than MA-CTL patients. Logistic regression analyses identified male sex, alcoholism, and hypertension as independent factors associated with MA-CMP with the following respective adjusted odds ratios (OR) of 3.791 (95% confidence interval [CI]: 2.508 to ...Continue Reading

Citations

Apr 3, 2020·Annals of Internal Medicine·Nora D Volkow
May 30, 2020·Journal of the American Heart Association·Pavan K V ReddyUri Elkayam
Aug 3, 2020·HIV Medicine·Tcs MartinD M Smith
Jan 1, 2018·Advances in Pulmonary Hypertension·Ramon L RamirezRoham T Zamanian
Aug 23, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Christopher G KevilA Wayne Orr
Feb 6, 2021·Clinics in Chest Medicine·Ramon L RamirezRoham T Zamanian
Oct 17, 2020·Annals of the American Thoracic Society·Nicholas A KolaitisUNKNOWN Pulmonary Hypertension Association Registry Investigators
Apr 1, 2021·European Journal of Pharmacology·Hicham LabaziMargaret R MacLean
Apr 14, 2021·BMC Genomics·Hasitha ChavvaBoyd R Rorabaugh
Jul 15, 2021·Circulation. Cardiovascular Quality and Outcomes·Susan X ZhaoMichael H Crawford
Aug 10, 2021·Journal of the American Heart Association·Stephen D DicksonLaith Alshawabkeh
Aug 17, 2021·Journal of Clinical Pharmacology·C Michael WhiteAnne N Nafziger
Nov 10, 2021·The American Journal of Drug and Alcohol Abuse·Zheng DaiGordon S Smith
Dec 29, 2021·Circulation. Arrhythmia and Electrophysiology·Paari DominicBrian Olshansky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

© 2022 Meta ULC. All rights reserved